Literature DB >> 29936060

Tumor budding is associated with poor prognosis of oral squamous cell carcinoma and histologically represents an epithelial-mesenchymal transition process.

Kyoung-Ok Hong1, Kyu-Young Oh1, Wui-Jung Shin1, Hye-Jung Yoon1, Jae-Il Lee1, Seong-Doo Hong2.   

Abstract

In this study, we aimed to identify whether tumor budding is associated with the progression and prognosis of oral squamous cell carcinoma (OSCC) and investigate the correlation between tumor budding and regulators of epithelial-mesenchymal transition (EMT). Fifty-six cases of OSCC were selected and their tumor budding status was reviewed using archived hematoxylin and eosin-stained slides. In addition, the expression of EMT regulators was evaluated by immunohistochemistry using antibodies against Snail and Twist. Tumor budding was observed in 19 (33.9%) of the 56 cases of OSCC. Tumor budding was strongly associated with lymph node metastasis (P = .001) and shorter overall survival (P = .002). The expression of Snail and Twist was correlated with lymph node metastasis (P < .001 and .002, respectively) and poorer overall survival (P = .024 and .024, respectively). Tumor budding was significantly associated with the expression of Snail (P = .003) and showed a tendency toward higher expression of Twist (P = .08). Therefore, our results suggest that tumor budding is significantly associated with poor prognosis in patients with OSCC and histologically represents an EMT process in OSCC.
Copyright © 2018. Published by Elsevier Inc.

Entities:  

Keywords:  Epithelial-mesenchymal transition (EMT); Oral squamous cell carcinoma; Snail; Tumor budding; Twist

Mesh:

Year:  2018        PMID: 29936060     DOI: 10.1016/j.humpath.2018.06.012

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  7 in total

1.  Tumor budding is an adverse prognostic marker in intestinal-type sinonasal adenocarcinoma and seems to be unrelated to epithelial-mesenchymal transition.

Authors:  Valeria Maffeis; Rocco Cappellesso; Francesca Galuppini; Vincenza Guzzardo; Alessia Zanon; Diego Cazzador; Enzo Emanuelli; Laura Ventura; Alessandro Martini; Ambrogio Fassina
Journal:  Virchows Arch       Date:  2020-01-24       Impact factor: 4.064

Review 2.  Tumour budding in solid cancers.

Authors:  Alessandro Lugli; Inti Zlobec; Martin D Berger; Richard Kirsch; Iris D Nagtegaal
Journal:  Nat Rev Clin Oncol       Date:  2020-09-08       Impact factor: 66.675

3.  Novel Criteria for Intratumoral Budding with Prognostic Relevance for Colon Cancer and Its Histological Subtypes.

Authors:  Pantea Pour Farid; Markus Eckstein; Susanne Merkel; Robert Grützmann; Arndt Hartmann; Volker Bruns; Michaela Benz; Regine Schneider-Stock; Carol I Geppert
Journal:  Int J Mol Sci       Date:  2021-12-03       Impact factor: 5.923

Review 4.  The Emerging Impact of Tumor Budding in Oral Squamous Cell Carcinoma: Main Issues and Clinical Relevance of a New Prognostic Marker.

Authors:  Lucrezia Togni; Vito Carlo Alberto Caponio; Nicoletta Zerman; Giuseppe Troiano; Khrystyna Zhurakivska; Lorenzo Lo Muzio; Andrea Balercia; Marco Mascitti; Andrea Santarelli
Journal:  Cancers (Basel)       Date:  2022-07-22       Impact factor: 6.575

5.  Post-neoadjuvant assessment of tumour budding according to ITBCC subgroups delivers stage- and regression-grade independent prognostic information in intestinal-type gastric adenocarcinoma.

Authors:  Moritz Jesinghaus; Anna-Lina Herz; Meike Kohlruss; Miguel Silva; Albert Grass; Sebastian Lange; Alexander Novotny; Katja Ott; Thomas Schmidt; Matthias Gaida; Alexander Hapfelmeier; Carsten Denkert; Wilko Weichert; Gisela Keller
Journal:  J Pathol Clin Res       Date:  2022-06-17

6.  Expression of SLC17A9 in hepatocellular carcinoma and its clinical significance.

Authors:  Jingdong Wu; Yongfei Yang; Jiansheng Song
Journal:  Oncol Lett       Date:  2020-08-31       Impact factor: 2.967

7.  The prognostic value of tumor budding in laryngeal squamous cell carcinoma.

Authors:  Heng Zhang; Xiaoli Sheng; Siyi Zhang; Xia Gu
Journal:  Transl Cancer Res       Date:  2020-01       Impact factor: 1.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.